Smart Investing in Antimicrobial Resistance Solutions Disrupts Biotech Market
Taxis Pharmaceuticals2025-08-19T14:17:43-04:00Antimicrobial resistance (AMR) has quickly become one of the most pressing health and economic challenges of our time, and it's creating an inflection point for biotech innovation and investment. With at least 1.27 million deaths attributed to AMR annually, the cost of inaction is clear. Beyond a moral obligation, investment in AMR is also a smart economic decision, and investors have begun disrupting the biotech market by supporting the momentum of the novel AMR solution pipeline.